MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
NovoCure Inc. (NASDAQ:NVCR)*
Organization & Developments: Novocure
Parents
NovoCure Inc. (NASDAQ:NVCR)*
Children
*Its lead product is Tumor Treating Fields (TTFields) which is currently being tested in trials to treat Non-small cell lung cancer (NSCLC), ovarian cancer and pancreatic cancer
2011: NovoTTF-100A for Treatment of Brain Tumors Wins FDA Clearance (2011)
2016: Novocure: Buying Opportunity? - NovoCure (NASDAQ:NVCR)
2016: Novocure's TTFields Therapy Could Become The Standard Adjunct Therapy In Various Solid Tumors. - NovoCure (NASDAQ:NVCR)
2017: Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients
2017: Novocure's device-chemo combo boosts survival in pancreatic cancer
2018: NovoCure: 2018 Off To A Strong Start For Optune_seekingalpha.com
2018: NovoCure: This Former ROTY Contender Is Far From Finished - NovoCure (NASDAQ:NVCR)
2018: NovoCure: Updates To Thesis And 2019 Outlook_
2018: NovoCure: Updates To Thesis And Stellar Data Looms_seekingalpha.com
2019: How This Red-Hot Medical Stock Is Using Electricity To Battle Cancer_www.investors.com
2019: NovoCure: Addressable Market For TTFields Continues To Expand With Mesothelioma Approval_seekingalpha.com
2019: NovoCure: Good News On All Fronts_seekingalpha.com
2020: Merck taps Novocure's cancer-fighting electric fields for new Keytruda combination study
2020: Novocure: A Disruptive Growth Play In Cancer Treatments
2020: What's Behind NovoCure's Recent Gains And What's Ahead
2021: Novocure Ltd.: A Shockingly Good Potential Ten Bagger
2021: Novocure Soars After Interim Results Suggest It Should Accelerate Cancer Test
2021: Novocure Stock Flashes Sell Signal After Liver Cancer Test Disappoints
2021: NovoCure: The Next Big Healthcare Acquisition
2022: NovoCure: Does The Reward Outweigh The Risk? I Believe So_seekingalpha.com
2022: NovoCure: Entering The Next Leaping Growth Phase_ seekingalpha.com
2022: NovoCure's Stock Could Soar In 2023_ seekingalpha.com
2023: Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
2023: NovoCure Electrifies NSCLC Space with Pivotal Phase III Win
2023: Novocure lays off 200 workers in plan to shave $60M off expenses
2023: NovoCure: Catalysts Stacking For More Upside_seekingalpha.com
2024: Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds FacebookXLinkedInShare Licensing
2024: FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
2024: NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation
2024: Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields_
2024: NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer
2024: NovoCure: Sell The METIS-Inspired Rally
2024: NovoCure: Stay Cautious Amid Positive Signs_ seekingalpha.com
2024: NovoCure: There Is Still More Upside
2024: NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
2024:P Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
2025 NovoCure Limited: Profitability Remains Elusive
2025: Novocure makes tumor-treating fields FDA PMA submission for treating pancreatic cancer
2025: NovoCure Q4 2024 Earnings: Strong And Growing Pipeline
2025: Novocure seeks approval after pancreatic cancer wearable scores at Phase III
2025: Novocure study shows improved pancreatic cancer survival
2025: Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
2025: Novocure wins CE mark for its lung cancer treatment wearable
2025: NovoCure: Loading Up On Growth Catalysts
2025: Novocure’s device for metastatic NSCLC treatment gains CE Mark
2026: Novocure wins FDA nod for Optune Pax for pancreatic cancer
Jumps
*Key People: Novocure
Finance & Acquisitions: Novocure